SGIOY Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2024 @ 21:59):
Our systems believe the stock currently is overvalued by -0.03% compare to its pairs and should correct downwards.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...

Stats
Dagens volum	213 331
Gjennomsnittsvolum	129 788
Markedsverdi	11.18B
EPS	$122.20 ( Q4 \| 2024-03-31 )
Neste inntjeningsdato	( $0 ) 2024-07-29
Last Dividend	$0.121 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	11.16 (Sector) 0 (Industry) 0
ATR14	$0.0110 (0.11%)

ACRDF 0.00%

ACRHF 0.00%

APNHY 0.00%

AVTBF 0.63%

AYRWF -14.89%

BBBT 0.00%

BLMS -9.09%

CBDHF 0.00%

CBGL 0.00%

CCHWF -21.71%

CENBF 0.00%

CHALF -99.00%

CNTTQ 0.00%

CRLBF -11.73%

CRYM -1.48%

DVAXW 9 900.00%

DVLP 0.00%

EAPH 12.03%

EDXC 55.17%

EMHTF 0.00%

ESALF -2.11%

ESALY 12.50%

ETST 11.90%

GDNSF -3.00%

GLASF 0.00%

GNHAY -15.36%

GRAMF 9 900.00%

HCANF 0.00%

HKMPY 0.00%

HLUYY 0.00%

HYEX -1.11%

HYPMY 0.00%

IPSEY 1.06%

ITHUF -18.67%

JUSHF 20.00%

KGKG 0.00%

LOWLF 0.00%

LVRLF 0.00%

MILC -1.14%

MKKGY -66.67%

NLBS 0.00%

NPHC 0.00%

NPPNY 0.00%

NUNZ 7.50%

ORXOY 2.13%

PLNHF 0.00%

PZOO -26.83%

RLBD 1.82%

RWBYF 0.21%

SGIOY 0.00%

TAIPY -12.10%

TCNNF 0.00%

TEVJF 0.00%

TLGTQ -11.79%

TRSSF -7.41%

UNRV -2.59%

VEXTF -13.10%

VLNCD 0.00%

VRNOF 0.00%

Korrelasjon (AI algo v.1.1b): Overvalued: -0.03% $9.71 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: -0.08 (neutral)

Signal:(54.573) Neutral

Shionogi & Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shionogi & Co., Ltd. Korrelasjon - Valuta/Råvare

0.15
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.53
( weak negative )

-0.24
( neutral )

Shionogi & Co., Ltd. Økonomi

Annual	2024
Omsetning:	$435.08B
Bruttogevinst:	$369.09B (84.83 %)
EPS:	$558.51

FY	2024
Omsetning:	$435.08B
Bruttogevinst:	$369.09B (84.83 %)
EPS:	$558.51

FY	2023
Omsetning:	$426.68B
Bruttogevinst:	$356.58B (83.57 %)
EPS:	$621.31

FY	2022
Omsetning:	$335.14B
Bruttogevinst:	$272.41B (81.28 %)
EPS:	$378.75

Financial Reports:

No articles found.

Shionogi & Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Shionogi & Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.85 - Stable (16.96%)

Information

First Dividend	$0.124	2021-03-29
Last Dividend	$0.121	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.245	--
Avg. Dividend % Per Year	0.00%	--
Score	3.71	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.85
Div. Directional Score	8.95	--

Next Divdend (Est)
(2024-12-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.71

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
28 Sep 2021	$0.121	30 Nov -0001	30 Nov -0001	30 Nov -0001
29 Mar 2021	$0.124	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
UEPCN	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
EPOKY	Ex Dividend Knight	2023-10-23	Semi-Annually	0.00%
PSBQ	Ex Dividend Junior	2023-07-06	Annually	0.00%
CHDRY	Ex Dividend Knight	2023-12-04	Semi-Annually	0.00%
LGFRY	Ex Dividend Junior	2023-07-06	Semi-Annually	0.00%
AGLXY	Ex Dividend Junior	2023-08-23	Annually	0.00%
YKLTF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
GXYYY	Ex Dividend Knight	2023-09-25	Annually	0.00%
SOMC	Ex Dividend Knight	2023-07-13	Quarterly	0.00%
CPKF	Ex Dividend Knight	2023-08-31	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.372	1.500	2.55	3.83	[0 - 0.5]
returnOnAssetsTTM	0.114	1.200	6.19	7.43	[0 - 0.3]
returnOnEquityTTM	0.135	1.500	9.61	10.00	[0.1 - 1]
payoutRatioTTM	0.277	-1.000	7.23	-7.23	[0 - 1]
currentRatioTTM	5.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.20	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.67	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00820	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	19.09	1.000	4.04	4.04	[3 - 30]
operatingCashFlowPerShareTTM	541.64	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	442.41	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00941	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.859	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.394	1.000	4.12	4.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	13.28	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.307	0.800	-1.286	-1.029	[0.5 - 2]
Total Score				12.06

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	2.75	1.000	9.82	0	[1 - 100]
returnOnEquityTTM	0.135	2.50	9.75	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	442.41	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00550	1.500	9.86	0	[0 - 0.4]
operatingCashFlowPerShareTTM	541.64	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.277	1.500	7.23	-7.23	[0 - 1]
pegRatioTTM	0.00219	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.355	1.000	3.63	0	[0.1 - 0.5]
Total Score				5.85

Shionogi & Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.